Heart Failure Drug Proves a Smart Investment Across EU and US

Researchers looked at whether a heart medication called digitoxin actually saves money while helping patients with a weak heart pump. The study focused on people with reduced ejection fraction, a condition where the heart cannot squeeze out enough blood with each beat. Doctors already know digitoxin can lower the chance of dying or ending up in the hospital from worsening heart failure. The big question was whether it makes financial sense for healthcare systems to add it to standard treatment.

The team built a computer model using data from a major trial called DIGIT-HF. That model followed patients through different health states over ten years and over their entire lifetime. Things like hospital costs, quality of life scores, and how much different countries are willing to pay for extra healthy years were adjusted for each region. They ran thousands of simulations to see how reliable the results were across all 27 EU countries and the United States.

In the EU, digitoxin paid off within the first ten years. Costs stayed very low, ranging from saving 338 euros to spending just 25 extra euros per patient. Patients gained between 0.19 and 0.23 quality-adjusted life years, which means more time living without symptoms getting in the way. The maximum cost per extra healthy year was only 120 euros, well below what most countries consider a fair price. Over a lifetime, the benefits grew even larger. Looking at the US, the drug actually saved money over a lifetime, around 405 dollars per patient, while still adding about 0.43 quality-adjusted life years.

In 24 of 27 EU countries, digitoxin was cheaper than standard care alone at the ten-year mark. By the end of life, ten countries still saw total savings. The chance that the drug offers good value for money was high everywhere, reaching 92% in the EU at common willingness-to-pay levels and over 93% in the US. The pattern made sense. Places with expensive hospital bills felt the financial benefit fastest because keeping patients out of the hospital saves a lot. Over longer time horizons, the gain in healthy years added up even more.